AnaptysBio, Inc. (NASDAQ:ANAB) Stock Has Consensus Price Target of $77.79 According to Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $77.79.

A number of research analysts have recently commented on ANAB shares. Scotiabank cut AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research note on Tuesday, August 25th. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a research note on Tuesday, September 22nd. Wolfe Research reissued an “outperform” rating and set a $78.00 price target on shares of AnaptysBio in a research note on Monday, August 31st. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $70.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Finally, Wall Street Zen downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research report on Sunday, October 4th.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $45.43 on Friday. The firm has a market capitalization of $1.36 billion, a PE ratio of 8.46 and a beta of 0.76. The stock’s fifty day moving average is $53.21 and its 200 day moving average is $57.33. AnaptysBio has a fifty-two week low of $20.18 and a fifty-two week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, topping the consensus estimate of ($0.46) by $5.57. The company had revenue of $27.49 million during the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same period in the previous year, the firm earned ($1.30) earnings per share. Equities analysts forecast that AnaptysBio will post -1.30 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other news, Director Hollings Renton sold 5,000 shares of AnaptysBio stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the sale, the director directly owned 10,995 shares in the company, valued at approximately $548,320.65. This trade represents a 31.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 31.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Persistent Asset Partners Ltd purchased a new stake in shares of AnaptysBio in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd grew its stake in AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 1,383 shares in the last quarter. State of Alaska Department of Revenue bought a new position in AnaptysBio in the third quarter worth approximately $85,000. Group One Trading LLC purchased a new position in AnaptysBio during the 2nd quarter worth $140,000. Finally, State of Wyoming purchased a new position in AnaptysBio during the 2nd quarter worth $158,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.